Contact Information
Address(Office)E12-3012 Ruiyu XIE
Phone(Office)8822 4975
(Lab)8822 2902
Fax8822 2314
Ph.D.Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona, USA (2004-2009)
B.Sc.Microbiology, Sun Yat-Sen (Zhongshan) University, Guangzhou, China (1996-2000)
2014-presentAssistant Professor, Faculty of Health Sciences,
University of Macau, Macao
2009 – 2014Postdoctoral Research Fellow, UCSD Stem Cell Program, University of California San Diego, La Jolla, California, USA
Research Interests
Increasing evidence suggests that epigenetic regulation of chromatin states strongly influences gene expression and cell fate choices, and its deregulation could therefore be a critical aspect to development and disease. My research focuses on understanding how chromatin-modifying enzymes control cell fate decisions during pancreas development, and elucidating the epigenetic and transcriptional mechanisms that underlie pancreatic lesion. We utilized both mouse genetic approaches and a parallel hESC-based in vitro differentiation system which recapitulates the sequence of events observed during in vivo pancreas development, where pluripotent cells first commit to endoderm, then primitive gut tube, posterior foregut, and subsequently pancreas. Using this differentiation platform, we have begun to dissect the epigenetic events that drive pancreatic development. Additional ongoing research in my laboratory includes:

  1. Using high-throughput sequencing and genome-editing technologies to study the DNA and histone modifications in pancreatic cancer, elucidating the role of chromatin modification enzymes in mouse models, and exploring novel anti-cancer or preventive strategies by targeting key epigenetic pathways.
  2. In vitro differentiation of patient-specific iPS/hES cells as models of pancreatic diseases, such as diabetes mellitus
Representative Publications
  • Zhang H, Wang Y, Dou J, Guo Y, He J, Li L, Liu X, Chen R, Deng R, Huang J, Xie R, Zhao X, Yu J. Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis. Oncogene. 2018 Oct 10.[Epub ahead of print]
  • Wu X, Li G, Xie R. Decoding the role of TET family dioxygenases in lineage specification. Epigenetics & Chromatin. 2018, 11(1):58. Review.
  • Li J, Wu X, Zhou Y, Lee M, Guo L, Han W, Mo W, Cao WM, Sun D*, Xie R*, Huang Y*. Decoding the dynamic DNA methylation and hydroxymethylation landscapes in endodermal lineage intermediates during pancreatic differentiation of hESC. Nucleic Acids Res. 2018, [Epub ahead of print]. (*co-corresponding author)
  • Ye J, Yuen SM, Murphy G, Xie R*, Kwok HF*. Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur J Pharm Sci. 2017, 110:62-69. (*co-corresponding author)
  • Niu Y, Li Q, Xie R, Liu S, Wang R, Xing P, Shi Y, Wang Y, Dong L, Wang C. Modulating the phenotype of host macrophages to enhance osteogenesis in MSC-laden hydrogels: Design of a glucomannan coating material. Biomaterials. 2017, 139:39-55.
  • Shih, HP; Seymour, PA; Patel, NA; Xie, R; Wang, A; Liu, PP; Yeo, GW; Magnuson, MA; Sander, M. A Gene Regulatory Network Cooperatively Controlled by Pdx1 and Sox9 Governs Lineage Allocation of Foregut Progenitor Cells. Cell reports2015, 13;13(2):326-36.
  • Wang, A; Yue, F; Li, Y; Xie, R; Harper, T; Patel, NA; Muth, K; Palmer, J; Qiu, Y; Wang, J; Lam, DK; Raum, JC; Stoffers, DA; Ren, B; Sander M. Epigenetic priming of enhancers predicts developmental competence of hESC-Derived endodermal lineage intermediates. Cell Stem Cell. 2015, 16(4):386-99.
  • Xie, R; Carrano, AC; Sander, M. A systems view of epigenetic networks regulating pancreas development and β-cell function. Wiley Interdiscip Rev Syst Biol Med. 2015, 7(1):1-11.
  • Zhang, F*; Xie, R*; Lau, SS; Monks, TJ. PARP-1 hyperactivation and reciprocal elevations in intracellular Ca2+ during ROS-induced non-apoptotic cell death. Toxicol. Sci. 2014, 140(1), 118-34. (*Equal contribution)
  • Xie, R; Everett, LJ; Lim, HW; Patel, NA; Schug, J; Kroon, E; Kelly, OG; Wang, A; D’Amour, KA; Robins, AJ; Won, KJ; Kaestner, KH; Sander, M. Dynamic chromatin remodeling mediated by Polycomb proteins orchestrates pancreatic differentiation of human embryonic stem cells. Cell Stem Cell. 2013, 12(2), 224-237.
  • van der Meulen, T; Xie, R; Kelly, OG; Vale, WW; Sander, M; Huising, MO. Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells. PLOS One.2012, 7(12), e52181.
  • Morán, I; Akerman, I; van de Bunt, M; Xie, R; Benazra, M; Nammo, T; Arnes, L; Nakić, N; García-Hurtado, J; Rodríguez-Seguí, S; Pasquali, L; Sauty-Colace, C; Beucher, A; Scharfmann, R; van Arensbergen, J; Johnson, PR; Berry, A; Lee, C; Harkins, T; Gmyr, V; Pattou, F; Kerr-Conte, J; Piemonti, L; Berney, T; Hanley, N; Gloyn, AL; Sussel, L; Langman, L; Brayman, KL; Sander, M; McCarthy, MI; Ravassard, P; Ferrer, J. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metabolism. 2012, 16(4), 435-448.
  • Seymour, PA; Shih, HP; Patel, NA; Freude, KK; Xie, R; Lim, CJ; Sander, M. A Sox9/Fgf feed-forward loop maintains pancreatic organ identity. Development. 2012, 139(18), 3363-72.
  • Monks, TJ; Xie, R; Tikoo, K; Lau, SS. ROS-induced histone modifications and their role in cell survival and cell death. Drug Metab Rev. 2006, 38(4), 755-767.
  • Xie, R; Zhuang, M; Ross, LS; Gomez, I; Oltean, DI; Bravo, A; Soberon, M; Gill, SS. Single amino acid mutations in the cadherin receptor from Heliothis virescens affect its toxin binding ability to Cry1A toxins. J Biol Chem. 2005, 280(9), 8416-8425.
  • Yu, J; Xie, R; Tan, L; Xu, W; Zeng, S; Chen, J; Tang, M; Pang, Y. Expression of the full-length and 3′-spliced cry1Ab gene in the 135-kDa crystal protein minus derivative of Bacillus thuringiensis subsp. kyushuensisCurr Microbiol. 2002, 45(2), 133-138.
Research Grants
  1. 2018-2021 (PI) The roles of PRDM16 in pancreatic ductal adenocarcinoma. [The Macau Fund for the Development of Science and Technology (FDCT)]
  2. 2018-2020 (PI) Dissecting the roles of TET hydroxylases in enhancer priming during endoderm lineage specification. [National Natural Science Foundation of China(NSFC)]
  3. 2017-2019 (PI) Developing multicellular pancreatic endoderm clusters for cell replacement therapies in diabetes. [University of Macau Multi Year   Research Grant (MYRG)]
  4. 2014-2017 (PI) The role of PRDMs in epigenetic regulation of pancreas development. [University of Macau Start-up Research Grant (SRG)]
  5. 2013-2014 (PI) Transcriptional and epigenetic regulation in pancreas development and beta-cell specification [California Institute for Regenerative Medicine (CIRM)]
2012Scholarship Award, Beta Cell Biology Consortium Investigator Retreat
2011Scholarship Award, Beta Cell Biology Consortium Investigator Retreat
2008Conference Grant, PARP 17th International Symposium on Poly(ADP-reibosyl)ation
2008Finalist and honorable mention for Carl C. Smith Mechanisms Specialty Section manuscript award, Society of Toxicology Annual Meeting
2007Drug Discovery Specialty Section Travel Award, Society of Toxicology Annual Meeting
2006Graduate Student Travel Award, American Society for Pharmacology and Experimental Therapeutics
Professional Activities
MemberAmerican Association for Cancer Research
MemberInternational Society for Stem Cell Research